{"id":"ipragliflozin","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Sodium/glucose cotransporter 2","category":"target"},{"label":"SLC5A2","category":"gene"},{"label":"SLC5A1","category":"gene"},{"label":"A10BK05","category":"atc"},{"label":"Active","category":"status"},{"label":"Diabetes mellitus type 1","category":"indication"},{"label":"Diabetes mellitus type 2","category":"indication"},{"label":"Hypoglycemic Agents","category":"pharmacology"},{"label":"Sodium-Glucose Transporter 2 Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":57.931,"date":"","count":18,"signal":"Cerebral infarction","source":"DrugCentral FAERS","actionTaken":"Reported 18 times (LLR=58)"},{"llr":40.749,"date":"","count":12,"signal":"Diabetes mellitus inadequate control","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=41)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=IPRAGLIFLOZIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:43:52.983859+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Ipragliflozin","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:43:59.979430+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:02:29.905217+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:43:58.533843+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IPRAGLIFLOZIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:43:58.937698+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Sodium/glucose cotransporter 2 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:43:59.979334+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2018096/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:43:59.631557+00:00"}},"allNames":"suglat","offLabel":[],"synonyms":["ipragliflozin","suglat","ipragliflozin L-proline","ASP1941"],"timeline":[{"date":"2014-01-17","type":"positive","source":"DrugCentral","milestone":"PMDA approval"}],"aiSummary":"Ipragliflozin (Suglat) is a marketed SGLT2 inhibitor primarily indicated for Type 1 Diabetes Mellitus, competing in a crowded market with several other SGLT2 inhibitors. Its key strength lies in its mechanism of action, which effectively blocks glucose reabsorption in the kidneys, leading to glucose excretion in the urine. The primary risk is the impending patent expiry in 2028, which could lead to increased competition from generic versions.","approvals":[{"date":"2014-01-17","orphan":false,"company":"","regulator":"PMDA"}],"brandName":"Suglat","ecosystem":[{"indication":"Diabetes mellitus type 1","otherDrugs":[{"name":"dapagliflozin","slug":"dapagliflozin","company":"Astrazeneca Ab"},{"name":"insulin glargine","slug":"insulin-glargine","company":"Sanofi Aventis Us"},{"name":"insulin human","slug":"insulin-human","company":"Lilly"},{"name":"insulin lispro","slug":"insulin-lispro","company":"Lilly"}],"globalPrevalence":null},{"indication":"Diabetes mellitus type 2","otherDrugs":[{"name":"acarbose","slug":"acarbose","company":"Bayer Hlthcare"},{"name":"acetohexamide","slug":"acetohexamide","company":"Lilly"},{"name":"albiglutide","slug":"albiglutide","company":"Glaxosmithkline Llc"},{"name":"alogliptin","slug":"alogliptin","company":"Takeda Pharms Usa"}],"globalPrevalence":537000000}],"mechanism":{"target":"Sodium/glucose cotransporter 2","targets":[{"gene":"SLC5A2","source":"DrugCentral","target":"Sodium/glucose cotransporter 2","protein":"Sodium/glucose cotransporter 2"},{"gene":"SLC5A1","source":"DrugCentral","target":"Sodium/glucose cotransporter 1","protein":"Sodium/glucose cotransporter 1"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Suglat is a competitive inhibitor of the sodium/glucose cotransporter 2 (SGLT2), a protein responsible for the reabsorption of glucose in the proximal convoluted tubule of the kidneys. By inhibiting SGLT2, Suglat reduces glucose reabsorption and increases glucose excretion in the urine, leading to a decrease in blood glucose levels."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Ipragliflozin","title":"Ipragliflozin","extract":"Ipragliflozin is a pharmaceutical drug for treatment of type 2 diabetes. Ipragliflozin, jointly developed by Astellas Pharma and Kotobuki Pharmaceutical, was approved in Japan on January 17, 2014, and in Russia on May 22, 2019."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4890","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=IPRAGLIFLOZIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IPRAGLIFLOZIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Ipragliflozin","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T15:01:54.273460","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:44:01.572357+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"dapagliflozin","drugSlug":"dapagliflozin","fdaApproval":"2014-01-08","patentExpiry":"Sep 9, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"canagliflozin","drugSlug":"canagliflozin","fdaApproval":"2013-03-29","patentExpiry":"Jun 3, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"empagliflozin","drugSlug":"empagliflozin","fdaApproval":"2014-08-01","patentExpiry":"Oct 3, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ertugliflozin","drugSlug":"ertugliflozin","fdaApproval":"2017-12-19","patentExpiry":"Jul 13, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"sotagliflozin","drugSlug":"sotagliflozin","fdaApproval":"2023-05-26","patentExpiry":"Oct 7, 2030","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"ipragliflozin","indications":{"approved":[{"name":"Diabetes mellitus type 1","source":"DrugCentral","snomedId":46635009,"regulator":"FDA"},{"name":"Diabetes mellitus type 2","source":"DrugCentral","snomedId":44054006,"regulator":"FDA","usPrevalence":37300000,"globalPrevalence":537000000,"prevalenceMethod":"curated","prevalenceSource":"IDF Diabetes Atlas, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"dapagliflozin","brandName":"dapagliflozin","genericName":"dapagliflozin","approvalYear":"2014","relationship":"same-class"},{"drugId":"canagliflozin","brandName":"canagliflozin","genericName":"canagliflozin","approvalYear":"2013","relationship":"same-class"},{"drugId":"empagliflozin","brandName":"empagliflozin","genericName":"empagliflozin","approvalYear":"2014","relationship":"same-class"},{"drugId":"ertugliflozin","brandName":"ertugliflozin","genericName":"ertugliflozin","approvalYear":"2017","relationship":"same-class"},{"drugId":"sotagliflozin","brandName":"sotagliflozin","genericName":"sotagliflozin","approvalYear":"2023","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01135433","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-05-15","conditions":["Type 2 Diabetes Mellitus"],"enrollment":168,"completionDate":"2011-11-28"},{"nctId":"NCT01225081","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-09-15","conditions":["Type 2 Diabetes Mellitus"],"enrollment":152,"completionDate":"2012-04-28"},{"nctId":"NCT01242228","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-21","conditions":["Type 2 Diabetes Mellitus"],"enrollment":106,"completionDate":"2012-06-06"},{"nctId":"NCT01057628","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-01-13","conditions":["Type 2 Diabetes Mellitus"],"enrollment":130,"completionDate":"2010-11-06"},{"nctId":"NCT01242202","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-21","conditions":["Type 2 Diabetes Mellitus"],"enrollment":113,"completionDate":"2012-05-25"},{"nctId":"NCT01242215","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-09-17","conditions":["Type 2 Diabetes Mellitus"],"enrollment":243,"completionDate":"2012-04-25"},{"nctId":"NCT01316107","phase":"PHASE3","title":"A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-01-15","conditions":["Type 2 Diabetes Mellitus"],"enrollment":122,"completionDate":"2012-10-19"},{"nctId":"NCT01054092","phase":"PHASE3","title":"A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-01-14","conditions":["Type 2 Diabetes Mellitus"],"enrollment":182,"completionDate":"2011-07-22"},{"nctId":"NCT01071850","phase":"PHASE2","title":"A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-03-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":412,"completionDate":"2011-04-11"},{"nctId":"NCT01117584","phase":"PHASE2","title":"A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-04-06","conditions":["Type 2 Diabetes Mellitus"],"enrollment":343,"completionDate":"2011-04-01"},{"nctId":"NCT01316094","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-01-18","conditions":["Type 2 Diabetes Mellitus"],"enrollment":165,"completionDate":"2012-11-28"},{"nctId":"NCT05770687","phase":"","title":"SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study","status":"RECRUITING","sponsor":"Kiyuk Chang","startDate":"2020-08-01","conditions":["Myocardial Infarction","Diabetes Mellitus, Type 2"],"enrollment":1000,"completionDate":"2026-12-31"},{"nctId":"NCT00790660","phase":"PHASE2","title":"A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-10-23","conditions":["Diabetes Mellitus, Type 2"],"enrollment":61,"completionDate":"2009-03-06"},{"nctId":"NCT01097681","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal Impairment","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-02-16","conditions":["Type 2 Diabetes Mellitus"],"enrollment":25,"completionDate":"2010-06-18"},{"nctId":"NCT01514838","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Astellas Pharma Inc","startDate":"2012-04-23","conditions":["Type II Diabetes Mellitus"],"enrollment":46,"completionDate":"2012-10-19"},{"nctId":"NCT02452632","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2015-06-22","conditions":["Type 2 Diabetes Mellitus"],"enrollment":143,"completionDate":"2017-01-05"},{"nctId":"NCT01505426","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-11-28","conditions":["Type II Diabetes Mellitus"],"enrollment":171,"completionDate":"2013-01-14"},{"nctId":"NCT02897219","phase":"PHASE3","title":"A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-08-29","conditions":["Type 1 Diabetes Mellitus"],"enrollment":175,"completionDate":"2018-03-15"},{"nctId":"NCT01023945","phase":"PHASE1","title":"A Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-11-07","conditions":["Type 2 Diabetes Mellitus"],"enrollment":30,"completionDate":"2010-03-26"},{"nctId":"NCT02794792","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2016-05-11","conditions":["Type 2 Diabetes Mellitus"],"enrollment":268,"completionDate":"2017-06-20"},{"nctId":"NCT00621868","phase":"PHASE2","title":"A Study of ASP1941 in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-03-26","conditions":["Diabetes Mellitus"],"enrollment":361,"completionDate":"2009-03-14"},{"nctId":"NCT02529449","phase":"PHASE2","title":"Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2015-09-01","conditions":["Type 1 Diabetes Mellitus"],"enrollment":43,"completionDate":"2016-03-19"},{"nctId":"NCT02847091","phase":"PHASE4","title":"Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-07-29","conditions":["Type 2 Diabetes Mellitus"],"enrollment":103,"completionDate":"2017-11-09"},{"nctId":"NCT02175784","phase":"PHASE4","title":"A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-03-31","conditions":["Type 2 Diabetes Mellitus"],"enrollment":262,"completionDate":"2015-12-07"},{"nctId":"NCT01672762","phase":"PHASE3","title":"A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-05-25","conditions":["Type 2 Diabetes Mellitus"],"enrollment":174,"completionDate":"2013-04-13"},{"nctId":"NCT03118713","phase":"PHASE4","title":"A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria","status":"TERMINATED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2017-04-25","conditions":["Type 2 Diabetes Mellitus"],"enrollment":33,"completionDate":"2018-12-12"},{"nctId":"NCT02291874","phase":"PHASE4","title":"Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-10-08","conditions":["Type 2 Diabetes Mellitus"],"enrollment":100,"completionDate":"2016-07-07"},{"nctId":"NCT02479399","phase":"","title":"Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-07-17","conditions":["Type 2 Diabetes"],"enrollment":11412,"completionDate":"2018-10-16"},{"nctId":"NCT03076112","phase":"PHASE3","title":"Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2017-04-25","conditions":["Type 2 Diabetes Mellitus"],"enrollment":170,"completionDate":"2022-08-31"},{"nctId":"NCT02577003","phase":"PHASE3","title":"Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-09","conditions":["Type 2 Diabetes Mellitus"],"enrollment":143,"completionDate":"2016-11-25"},{"nctId":"NCT02564211","phase":"PHASE3","title":"Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-26","conditions":["Type 2 Diabetes Mellitus"],"enrollment":77,"completionDate":"2017-03-07"},{"nctId":"NCT02577016","phase":"PHASE3","title":"Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-05","conditions":["Type 2 Diabetes Mellitus"],"enrollment":141,"completionDate":"2016-11-18"},{"nctId":"NCT02317484","phase":"","title":"Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2014-11","conditions":["Diabetes Mellitus, Type 2"],"enrollment":231,"completionDate":"2018-02-28"},{"nctId":"NCT01611363","phase":"PHASE1","title":"A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2011-10-27","conditions":["Type 2 Diabetes Mellitus"],"enrollment":44,"completionDate":"2012-02-03"},{"nctId":"NCT01302028","phase":"PHASE1","title":"Renal Impairment Study With ASP1941","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-01-22","conditions":["Type 2 Diabetes Mellitus"],"enrollment":40,"completionDate":"2010-06-26"},{"nctId":"NCT01302145","phase":"PHASE1","title":"Drug to Drug Interaction Study With ASP1941 and Metformin","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-02-25","conditions":["Type 2 Diabetes Mellitus"],"enrollment":36,"completionDate":"2009-12-09"},{"nctId":"NCT02791035","phase":"PHASE4","title":"Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2016-06","conditions":["Type 2 Diabetes Mellitus"],"enrollment":100,"completionDate":"2017-03"},{"nctId":"NCT02875821","phase":"PHASE4","title":"Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-04-26","conditions":["Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)"],"enrollment":44,"completionDate":"2017-06-07"},{"nctId":"NCT02284269","phase":"","title":"Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Pharmaceuticals and Medical Devices Agency, Japan","startDate":"2014-10","conditions":["Diabetes Mellitus, Type 2"],"enrollment":18000,"completionDate":""},{"nctId":"NCT02297620","phase":"","title":"The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-04","conditions":["Type 2 Diabetes"],"enrollment":8687,"completionDate":"2015-07"},{"nctId":"NCT02528019","phase":"PHASE4","title":"Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors","status":"UNKNOWN","sponsor":"Kurume University","startDate":"2015-08","conditions":["Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications"],"enrollment":100,"completionDate":"2018-08"},{"nctId":"NCT01972880","phase":"PHASE1","title":"A Study to Compare the Oral Absorption of ASP1941 Among Two Types of Tablets","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-09","conditions":["Healthy","Plasma Concentration of ASP1941"],"enrollment":32,"completionDate":"2014-01"},{"nctId":"NCT01678287","phase":"PHASE1","title":"Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2007-11","conditions":["Healthy Volunteers","Pharmacokinetics of ASP1941"],"enrollment":65,"completionDate":"2008-01"},{"nctId":"NCT01674777","phase":"PHASE1","title":"A Study to Investigate the Effect of Food on the Absorption, Distribution and Elimination of ASP1941","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10","conditions":["Healthy","Pharmacokinetics of ASP1941"],"enrollment":30,"completionDate":"2010-12"},{"nctId":"NCT01611428","phase":"PHASE1","title":"Absolute Bioavailability Study With Ipragliflozin","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2011-06","conditions":["Bioavailability of Ipragliflozin","Healthy Subjects"],"enrollment":14,"completionDate":"2011-07"},{"nctId":"NCT01611415","phase":"PHASE1","title":"Drug to Drug Interaction Study With Ipragliflozin and Furosemide","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2011-07","conditions":["Healthy Subjects","Pharmacokinetics of Ipragliflozin"],"enrollment":24,"completionDate":"2011-10"},{"nctId":"NCT01373060","phase":"PHASE1","title":"A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of ASP1941 in Healthy Male Taiwanese Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-02","conditions":["Healthy","Pharmacokinetics of ASP1941"],"enrollment":56,"completionDate":"2011-03"},{"nctId":"NCT01403818","phase":"PHASE1","title":"A Study to Assess the Effect of ASP1941 and Mitiglinide on Their Plasma Concentration","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-06","conditions":["Healthy","Pharmacokinetics of ASP1941","Pharmacokinetics of Mitiglinide"],"enrollment":60,"completionDate":"2011-08"},{"nctId":"NCT01232413","phase":"PHASE1","title":"A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-09","conditions":["Healthy Subjects","Cardiac Repolarization"],"enrollment":88,"completionDate":"2011-02"},{"nctId":"NCT01302132","phase":"PHASE1","title":"Mass Balance Study of ASP1941","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-05","conditions":["Healthy Subjects"],"enrollment":6,"completionDate":"2008-10"},{"nctId":"NCT01302158","phase":"PHASE1","title":"Drug-drug Interaction Study With ASP1941 and Glimepiride","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-12","conditions":["Healthy Subjects"],"enrollment":52,"completionDate":"2010-04"},{"nctId":"NCT01288898","phase":"PHASE1","title":"Multiple Dose Escalating Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1941","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-05","conditions":["Healthy"],"enrollment":48,"completionDate":"2008-03"},{"nctId":"NCT01288885","phase":"PHASE1","title":"First in Men Study of Single Oral Doses of ASP1941 in Healthy Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-11","conditions":["Healthy"],"enrollment":76,"completionDate":"2007-05"},{"nctId":"NCT01187186","phase":"PHASE1","title":"A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-05","conditions":["Liver Disease"],"enrollment":16,"completionDate":"2010-08"},{"nctId":"NCT01099839","phase":"PHASE1","title":"A Study to Assess Drug-Drug Interaction Between ASP1941 and Miglitol","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-02","conditions":["Healthy Volunteers","Pharmacokinetics of ASP1941"],"enrollment":30,"completionDate":"2010-04"},{"nctId":"NCT01121198","phase":"PHASE1","title":"A Study to Assess Safety and Tolerability of ASP1941 After Single and Repeated Administration in Healthy Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-12","conditions":["Healthy Volunteer","Pharmacokinetics of ASP1941"],"enrollment":84,"completionDate":"2007-07"},{"nctId":"NCT01104532","phase":"PHASE1","title":"A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-02","conditions":["Healthy","Pharmacokinetics of ASP1941"],"enrollment":64,"completionDate":"2010-03"},{"nctId":"NCT01088919","phase":"PHASE1","title":"A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-11","conditions":["Healthy","Pharmacokinetics of ASP1941"],"enrollment":64,"completionDate":"2009-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"3N2N8OOR7X","CHEBI":"CHEBI:134724","INN_ID":"9258","UMLSCUI":"C3492889","chemblId":"CHEMBL2018096","ChEMBL_ID":"CHEMBL2018096","KEGG_DRUG":"D10196","DRUGBANK_ID":"DB11698","PUBCHEM_CID":"10453870","IUPHAR_LIGAND_ID":"9394","SECONDARY_CAS_RN":"951382-34-6","MESH_SUPPLEMENTAL_RECORD_UI":"C572941"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":333,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A10BK05","allCodes":["A10BK05"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"2014","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2014-01-17T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:44:01.572357+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}